Immune response to an indigenously developed r-Hepatitis B vaccine in mixed population: Study of an accelerated vaccination schedule

Table 1 Flowchart of the events.

CRITERIA	d -7	d 0	d 30	d 60	d 90
Informed consent		v
Medical history	v
Physical exam/signs and symptoms	v	v	v	v
Hepatitis B vaccine		v	v	v
Adverse experiences		v	v	v	v
Specialty tests-HIV	v
Hematology & ESR	v				v
Liver function test	v				v
Renal function test	v				v
HBsAg	v
Anti-HBs Ab	v				v
Anti-HBc IgM	v

Table 2 Immunogenicity analysis in subjects after three doses of vaccination.

Groups	30th d					60th d					90th d
	GMT	AMT (mean ± SE)	Confidence Level (95%)		% SC	GMT	AMT(mean ± SE)	Confidence Level (95%)		% SC	GMT	AMT	Confidence Level (95%)		% SC
			U	L				U	L			(mean ± SE)	U	L
BEVAC	13.77	33.30± 9.86	52.83	13.76	100	519.84	632.67± 3.94	709.77	555.56	100	2 627.58	4529.19± 79.79	6 073.13	2 985.25	100
ENGERIX-B	10.95	22.40±10.52	43.65	1.15	100	475.46	557.00±50.55	659.08	454.91	100	2272.72	3523.93±800.56	5140.71	1907.14	100
TWO-WAY	NS (Between the groups)					NS (Between the groups)					NS (Between the Groups)
ANOVA

GMT – geometric mean titer, AMT – arithmetic mean titer, SEM – standard error of mean , NS – non-significant .